Results 151 to 160 of about 55,676 (335)

Levetiracetam Reduces Early Inflammatory Response After Experimental Intracerebral Hemorrhage by Regulating the Janus Kinase 2 (JAK2)–Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway

, 2020
Jing Xiong, Han Zhou, Donglin Lu, Zixuan Wang, Heng-Jian Liu, Yuqi Sun, Jinxiang Xu, Yugong Feng, Ang Xing   +8 more
openalex   +1 more source

Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study

, 2023
Lieke E.J.M. Scheepers, Yifei Yang, Yi Lung Chen, Graeme Jones   +3 more
openalex   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics

MedComm – Oncology
Janus Kinases (JAKs) play a crucial role as therapeutic targets for various cancers. However, the current JAK inhibitors (JAKi) available have limited therapeutic benefits due to their lack of selectivity.
Tian‐Hua Wei, Meng‐Yi Lu, Si‐Hui Yao, Yu‐Qi Hong, Jin Yang, Meng‐Yuan Zhang, Yu‐Qi Yin, Yu‐Jie Han, Qing‐Qing Li, Zi‐Xuan Wang, Yi‐Bo Wang, Zhen‐Jiang Tong, Yun Zhou, Wei‐Chen Dai, Yan‐Cheng Yu, Shan‐Liang Sun, Ye Yang, Nian‐Guang Li, Zhi‐Hao Shi   +18 more
doaj   +1 more source

Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial. [PDF]

Cancer Med, 2021
Spaner DE, Luo Y, Wang G, Gallagher J, Tsui H, Shi Y.   +5 more
europepmc   +1 more source

Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All

Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Inhibitors Targeting Multiple Janus Kinases From Zanthoxylum simulans Mediate Inhibition and Apoptosis Against Gastric Cancer Cells via the Estrogen Pathway. [PDF]

Front Chem, 2022
Tian YQ, Hu D, Zhang YL, Zou J, Chen GL, Guo MQ.   +5 more
europepmc   +1 more source

Narrow spectrum kinase inhibitors demonstrate promise for the treatment of dry eye disease and other ocular inflammatory disorders [PDF]

, 2018
Doughty, Michael, Foster, Martyn R., Fyfe, Matthew C.T., Hagan, Suzanne, Ofori-Frimpong, Boatemaa, Oliver, Katherine, Rowley, Adele, Sirohi, Sameer, Solanke, Yemisi, Taylor, Mike, Walshe, Claire A., Webber, Steve   +11 more
core   +1 more source

Role of Janus kinase-2 in insulin-mediated phosphorylation and inactivation of protein phosphatase-2A and its impact on upstream insulin signalling components [PDF]

, 1999
Najma BEGUM, Louis Ragolia
openalex   +1 more source